FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways.

Garima DixitJesus Gonzalez-BosquetJoseph SkurskiEric J DevorErin B DickersonWarren B NothnickPriya D IssureeKimberly K LeslieThorsten Maretzky

Published in: Clinical and translational medicine (2023)

These findings highlight a pivotal role of ADAM17 in the pathogenesis of EC and provide a compelling rationale for targeting ADAM17 protease activity in FGFR2-driven cancers.

Keyphrases

endometrial cancer
small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
social media
cancer therapy
cell proliferation
clinical trial
childhood cancer